The estimated Net Worth of Rosty Raykov is at least $2.3 Million dollars as of 31 August 2024. Rosty Raykov owns over 2,431 units of Fennec Pharmaceuticals Inc stock worth over $349,432 and over the last 7 years Rosty sold FENC stock worth over $1,948,616.
Rosty has made over 14 trades of the Fennec Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Rosty sold 2,431 units of FENC stock worth $13,419 on 31 August 2024.
The largest trade Rosty's ever made was exercising 323,961 units of Fennec Pharmaceuticals Inc stock on 13 August 2020 worth over $599,328. On average, Rosty trades about 27,026 units every 92 days since 2018. As of 31 August 2024 Rosty still owns at least 66,432 units of Fennec Pharmaceuticals Inc stock.
You can see the complete history of Rosty Raykov stock trades at the bottom of the page.
Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En... und Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include: